NASDAQ:MDXG MiMedx Group (MDXG) Stock Price, News & Analysis → [Shocking] Elon Musk’s Plan To End Banks (From Crypto 101 Media) (Ad) Free MDXG Stock Alerts $6.36 +0.07 (+1.11%) (As of 04/22/2024 ET) Add Compare Share Share Today's Range$6.25▼$6.4050-Day Range$6.16▼$8.6352-Week Range$3.49▼$9.27Volume622,981 shsAverage Volume784,436 shsMarket Capitalization$934.67 millionP/E Ratio19.88Dividend YieldN/APrice Target$12.25 Stock AnalysisStock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestSocial MediaStock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestSocial Media Get MiMedx Group alerts: Email Address MiMedx Group MarketRank™ Stock AnalysisAnalyst RatingBuy3.00 Rating ScoreUpside/Downside92.6% Upside$12.25 Price TargetShort InterestHealthy4.98% of Float Sold ShortDividend StrengthN/ASustainabilityN/ANews Sentiment0.56Based on 3 Articles This WeekInsider TradingSelling Shares$409,378 Sold Last QuarterProj. Earnings Growth42.42%From $0.33 to $0.47 Per ShareSee Full Details Hide Full Details Overall MarketRank™New Rank-Based ScoringMarketRank™ is calculated by averaging available category scores (with extra weight given to analysis and valuation), then ranking the company's weighted average against that of other companies.4.16 out of 5 starsMedical Sector145th out of 910 stocksSurgical & Medical Instruments Industry23rd out of 97 stocks 3.5 Analyst's Opinion Consensus RatingMiMedx Group has received a consensus rating of Buy. The company's average rating score is 3.00, and is based on 4 buy ratings, no hold ratings, and no sell ratings.Amount of Analyst CoverageMiMedx Group has only been the subject of 2 research reports in the past 90 days. Previous Next 4.0 Short Interest Percentage of Shares Shorted4.98% of the float of MiMedx Group has been sold short.Short Interest Ratio / Days to CoverMiMedx Group has a short interest ratio ("days to cover") of 6.8.Change versus previous monthShort interest in MiMedx Group has recently decreased by 6.16%, indicating that investor sentiment is improving significantly. Previous Next 0.0 Dividend Strength Dividend YieldMiMedx Group does not currently pay a dividend.Dividend GrowthMiMedx Group does not have a long track record of dividend growth. Previous Next N/A Sustainability and ESG Overall ESG (Environmental, Social, and Governance) ScoreThere is no current Upright™ data available for MDXG. Previous Next 2.0 News and Social Media Coverage News SentimentMiMedx Group has a news sentiment score of 0.56. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This news sentiment score is similar to the average news sentiment of Medical companies.News Coverage This WeekMarketBeat has tracked 3 news articles for MiMedx Group this week, compared to 2 articles on an average week.Search InterestOnly 6 people have searched for MDXG on MarketBeat in the last 30 days. This is a decrease of -33% compared to the previous 30 days.MarketBeat FollowsOnly 2 people have added MiMedx Group to their MarketBeat watchlist in the last 30 days. This is a decrease of -60% compared to the previous 30 days. Previous Next 3.3 Company Ownership Insider Buying vs. Insider SellingIn the past three months, MiMedx Group insiders have sold more of their company's stock than they have bought. Specifically, they have bought $0.00 in company stock and sold $409,378.00 in company stock.Percentage Held by Insiders19.90% of the stock of MiMedx Group is held by insiders. A high percentage of insider ownership can be a sign of company health.Percentage Held by Institutions79.15% of the stock of MiMedx Group is held by institutions. High institutional ownership can be a signal of strong market trust in this company. Previous Next 3.1 Earnings and Valuation Earnings GrowthEarnings for MiMedx Group are expected to grow by 42.42% in the coming year, from $0.33 to $0.47 per share.Price to Earnings Ratio vs. the MarketThe P/E ratio of MiMedx Group is 19.88, which means that it is trading at a less expensive P/E ratio than the market average P/E ratio of about 143.54.Price to Earnings Ratio vs. SectorThe P/E ratio of MiMedx Group is 19.88, which means that it is trading at a less expensive P/E ratio than the Medical sector average P/E ratio of about 239.64.Price to Book Value per Share RatioMiMedx Group has a P/B Ratio of 6.49. P/B Ratios above 3 indicate that a company could be overvalued with respect to its assets and liabilities. Previous Next See Top Rated MarketRank™ Stocks Here Ad Crypto 101 Media[Shocking] Elon Musk’s Plan To End BanksLeaked Elon Musk call reveals shocking plan to replace banks. As Musk's plan rolls out, industry experts predict it could spark a wave of mass crypto adoption. Triggering a new crypto bull run. While helping drive a booming crypto asset class up from $2.5-billion to $16-trillion (a 6,400x increase) by 2030. Click here now to get your copy. About MiMedx Group Stock (NASDAQ:MDXG)MiMedx Group, Inc. develops and distributes placental tissue allografts for various sectors of healthcare. It processes the human placental tissues utilizing its patented and proprietary PURION process to produce allografts that retains the tissue's inherent biological properties and regulatory proteins. The company's patented and proprietary processing method employs aseptic processing techniques in addition to terminal sterilization. Its products include EpiFix, a barrier membrane allograft used for the treatment of chronic wounds, including diabetic foot ulcers, venous leg ulcers, and pressure ulcers; AmnioFix, a protective barrier allograft, which comprises dehydrated human amnion/chorion membrane for use in surgical recovery applications; and EpiCord and AmnioCord are dehydrated human umbilical cord allografts that are used to provide a protective environment for the healing process, as well as used in the advanced wound care and surgical recovery applications. The company's products have applications in the areas of wound care, burn, surgical sectors of healthcare. The company sells its products through direct sales force and independent sales agents, as well as through independent distributors primarily in the United States. MiMedx Group, Inc. was incorporated in 2011 and is headquartered in Marietta, Georgia.Read More MDXG Stock Price History View Price History Chart DataSkip Price History Chart 30 days | 90 days | 365 days | Advanced Chart MDXG Stock News HeadlinesApril 18, 2024 | fool.comMiMedx Group (NASDAQ: MDXG)April 16, 2024 | globenewswire.comMIMEDX to Host First Quarter 2024 Operating and Financial Results Conference Call on April 30April 23, 2024 | Banyan Hill Publishing (Ad)Don’t Miss Out on the AI Gold Rush That’s Just Getting Started“Titan of Tech” Bets Big on Tiny AI Company He’s made as much as 3,250,000% in just three years on companies like Facebook, Airbnb, and PayPal… But our research shows his latest investment could be his most successful venture yet.April 13, 2024 | wsj.comMiMedx Group Inc.March 29, 2024 | stockhouse.comMIMEDX Provides Update on AXIOFILL® Request for Designation ("RFD") from FDAMarch 27, 2024 | msn.comMiMedx slips as FDA reaffirms position on AxiofillMarch 27, 2024 | finance.yahoo.comMIMEDX Provides Update on AXIOFILL® Request for Designation (“RFD”) from FDAMarch 22, 2024 | investing.comMiMedx secures exclusive rights to wound care productApril 23, 2024 | Banyan Hill Publishing (Ad)Don’t Miss Out on the AI Gold Rush That’s Just Getting Started“Titan of Tech” Bets Big on Tiny AI Company He’s made as much as 3,250,000% in just three years on companies like Facebook, Airbnb, and PayPal… But our research shows his latest investment could be his most successful venture yet.March 21, 2024 | markets.businessinsider.comNorthland Securities Keeps Their Buy Rating on MiMedx Group (MDXG)March 21, 2024 | finance.yahoo.comInvesting in MiMedx Group (NASDAQ:MDXG) a year ago would have delivered you a 138% gainMarch 20, 2024 | markets.businessinsider.comAnalysts Conflicted on These Healthcare Names: Diamedica Therapeutics (DMAC), Design Therapeutics (DSGN) and MiMedx Group (MDXG)March 20, 2024 | globenewswire.comMIMEDX Expands Portfolio with Fibrillar Collagen Wound DressingMarch 16, 2024 | finance.yahoo.comMDXG Apr 2024 7.500 callMarch 13, 2024 | finance.yahoo.comMIMEDX Introduces E-Commerce and Account Management PlatformMarch 12, 2024 | msn.comGeron slips as FDA reviews blood cancer therapy ahead of AdCom meetingMarch 4, 2024 | finance.yahoo.comMIMEDX Announces Appointment of Two New Independent DirectorsMarch 1, 2024 | finanznachrichten.deMiMedx Group, Inc: MIMEDX Announces Fourth Quarter and Full Year 2023 Operating and Financial ResultsMarch 1, 2024 | markets.businessinsider.comMizuho Maintains Buy Rating for MiMedx Group: Here's What You Need To KnowMarch 1, 2024 | finance.yahoo.comMiMedx Group Full Year 2023 Earnings: EPS Beats ExpectationsMarch 1, 2024 | finance.yahoo.comMiMedx Group, Inc.'s (NASDAQ:MDXG) Stock's On An Uptrend: Are Strong Financials Guiding The Market?February 29, 2024 | finance.yahoo.comMDXG: Another Beat & RaiseFebruary 29, 2024 | markets.businessinsider.comMiMedx Group: Strong Q4 Performance and Promising Growth Prospects Justify Buy RatingFebruary 29, 2024 | finance.yahoo.comMiMedx Group, Inc. (NASDAQ:MDXG) Q4 2023 Earnings Call TranscriptFebruary 28, 2024 | washingtonpost.comMiMedx: Q4 Earnings SnapshotFebruary 28, 2024 | finance.yahoo.comMiMedx Group Inc (MDXG) Reports Strong Year-Over-Year Sales Growth and Net Income Surge in Q4 ...February 28, 2024 | finance.yahoo.comMIMEDX Announces Fourth Quarter and Full Year 2023 Operating and Financial ResultsSee More Headlines Receive MDXG Stock News and Ratings via Email Sign-up to receive the latest news and ratings for MiMedx Group and its competitors with MarketBeat's FREE daily newsletter. Email Address Company Calendar Last Earnings2/28/2024Today4/23/2024Next Earnings (Confirmed)4/30/2024Fiscal Year End12/31/2024Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNASDAQ SectorMedical Industry Surgical & medical instruments Sub-IndustryN/A Current SymbolNASDAQ:MDXG CUSIPN/A CIK1376339 Webwww.mimedx.com Phone(770) 651-9100Fax678-384-6741Employees895Year FoundedN/APrice Target and Rating Average Stock Price Target$12.25 High Stock Price Target$14.00 Low Stock Price Target$11.00 Potential Upside/Downside+92.6%Consensus RatingBuy Rating Score (0-4)3.00 Research Coverage4 Analysts Profitability EPS (Most Recent Fiscal Year)$0.32 Trailing P/E Ratio19.88 Forward P/E Ratio19.27 P/E GrowthN/ANet Income$58.23 million Net Margins14.49% Pretax Margin9.53% Return on Equity41.12% Return on Assets6.04% Debt Debt-to-Equity Ratio0.34 Current Ratio3.57 Quick Ratio3.11 Sales & Book Value Annual Sales$321.48 million Price / Sales2.91 Cash Flow$0.19 per share Price / Cash Flow33.45 Book Value$0.98 per share Price / Book6.49Miscellaneous Outstanding Shares146,958,000Free Float117,713,000Market Cap$934.65 million OptionableOptionable Beta1.32 7 Stocks That Could Be Bigger Than Tesla, Nvidia, and GoogleGrowth stocks offer a lot of bang for your buck, and we've got the next upcoming superstars to strongly consider for your portfolio.Get This Free Report Key ExecutivesMr. William F. Hulse IV (Age 50)General Counsel & Chief Administrative Officer Comp: $677.36kDr. Robert Benjamin Stein M.D. (Age 73)Ph.D., President of Regenerative Medicine & Biologics Innovation Comp: $639.28kMr. Joseph H. Capper (Age 60)CEO & Director Mr. Douglas C. Rice CPA (Age 58)Chief Financial Officer Mr. Scott M. Turner (Age 58)Senior Vice President of Operations & Procurement Comp: $493.98kMr. Matthew M. NotarianniHead of Investor RelationsMr. Mark P. Graves (Age 58)Senior VP & Chief Compliance Officer Hilary DixonVice President of Investor Relations & Corporate Strategic CommunicationsMs. Kate SurdezChief Human Resources OfficerDr. David H. Mason Jr. (Age 77)Chief Medical Officer More ExecutivesKey CompetitorsIntersect ENTNASDAQ:XENTArtivionNYSE:AORTParagon 28NYSE:FNAAtrionNASDAQ:ATRIOrthoPediatricsNASDAQ:KIDSView All CompetitorsInsiders & InstitutionsAllspring Global Investments Holdings LLCSold 45,612 shares on 4/18/2024Ownership: 0.113%Register Financial Advisors LLCSold 4,000 shares on 4/16/2024Ownership: 0.023%William Frank Iv HulseSold 20,381 sharesTotal: $162,028.95 ($7.95/share)Fisher Asset Management LLCSold 48,818 shares on 3/5/2024Ownership: 0.298%Ricci S WhitlowSold 15,271 sharesTotal: $122,320.71 ($8.01/share)View All Insider TransactionsView All Institutional Transactions MDXG Stock Analysis - Frequently Asked Questions Should I buy or sell MiMedx Group stock right now? 4 Wall Street analysts have issued "buy," "hold," and "sell" ratings for MiMedx Group in the last year. There are currently 4 buy ratings for the stock. The consensus among Wall Street analysts is that investors should "buy" MDXG shares. View MDXG analyst ratings or view top-rated stocks. What is MiMedx Group's stock price target for 2024? 4 equities research analysts have issued 1-year price objectives for MiMedx Group's shares. Their MDXG share price targets range from $11.00 to $14.00. On average, they predict the company's share price to reach $12.25 in the next twelve months. This suggests a possible upside of 92.6% from the stock's current price. View analysts price targets for MDXG or view top-rated stocks among Wall Street analysts. How have MDXG shares performed in 2024? MiMedx Group's stock was trading at $8.77 at the beginning of 2024. Since then, MDXG shares have decreased by 27.5% and is now trading at $6.36. View the best growth stocks for 2024 here. When is MiMedx Group's next earnings date? The company is scheduled to release its next quarterly earnings announcement on Tuesday, April 30th 2024. View our MDXG earnings forecast. How can I listen to MiMedx Group's earnings call? MiMedx Group will be holding an earnings conference call on Tuesday, April 30th at 4:30 PM Eastern. Interested parties can register for or listen to the call using this link. How were MiMedx Group's earnings last quarter? MiMedx Group, Inc. (NASDAQ:MDXG) posted its quarterly earnings data on Wednesday, February, 28th. The company reported $0.04 earnings per share for the quarter, missing the consensus estimate of $0.08 by $0.04. The business had revenue of $86.83 million for the quarter, compared to the consensus estimate of $85.58 million. MiMedx Group had a trailing twelve-month return on equity of 41.12% and a net margin of 14.49%. Who are MiMedx Group's major shareholders? MiMedx Group's stock is owned by a number of institutional and retail investors. Top institutional shareholders include Allspring Global Investments Holdings LLC (0.11%) and Register Financial Advisors LLC (0.02%). Insiders that own company stock include Mark Graves, Peter M Carlson, Ricci S Whitlow, Rice Doug, Robert Benjamin Stein, Rohit Kashyap, Scott M Turner, Timothy R Wright, William Frank Iv Hulse and William Lawrence Phelan. View institutional ownership trends. How do I buy shares of MiMedx Group? Shares of MDXG stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. Compare Top Brokerages Here. This page (NASDAQ:MDXG) was last updated on 4/23/2024 by MarketBeat.com Staff From Our PartnersDon’t Miss Out on the AI Gold Rush That’s Just Getting StartedBanyan Hill PublishingHealthcare Takes A Big Step Forward With The Help Of AIThe Bull Reporttop AI stock (it’s not MSFT, GOOGL, AMZN or AAPL)Traders AgencyDid You Get Your Free Bitcoin Yet?Crypto Swap Profits[Shocking] Elon Musk’s Plan To End BanksCrypto 101 MediaForget Bitcoin. Crypto Millionaire Predicts 8,788% Gains For THISParadigm PressThe #1 Crypto for 2024InvestorPlaceMan Who Predicted 2008: “This Will be Worse.”Altimetry Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding MiMedx Group, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Get 30 Days of MarketBeat All Access Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: Best-in-Class Portfolio Monitoring View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. Stock Ideas and Recommendations Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report. Advanced Stock Screeners and Research Tools Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis. Start Your 30-Day Free Trial Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.